239 related articles for article (PubMed ID: 24667268)
1. [Vascular normalization and cancer immunotherapy].
Zeng J; Yuan D; Liu H; Song Y
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):273-6. PubMed ID: 24667268
[TBL] [Abstract][Full Text] [Related]
2. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Huang Y; Goel S; Duda DG; Fukumura D; Jain RK
Cancer Res; 2013 May; 73(10):2943-8. PubMed ID: 23440426
[TBL] [Abstract][Full Text] [Related]
3. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
4. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W
Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
6. LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
Bonanno L; Zulato E; Pavan A; Attili I; Pasello G; Conte P; Indraccolo S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995715
[TBL] [Abstract][Full Text] [Related]
7. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Huang Y; Yuan J; Righi E; Kamoun WS; Ancukiewicz M; Nezivar J; Santosuosso M; Martin JD; Martin MR; Vianello F; Leblanc P; Munn LL; Huang P; Duda DG; Fukumura D; Jain RK; Poznansky MC
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17561-6. PubMed ID: 23045683
[TBL] [Abstract][Full Text] [Related]
8. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
9. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y; Jung K
Exp Mol Med; 2023 Nov; 55(11):2308-2319. PubMed ID: 37907742
[TBL] [Abstract][Full Text] [Related]
10. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.
Shi S; Chen L; Huang G
Med Oncol; 2013 Dec; 30(4):698. PubMed ID: 23982676
[TBL] [Abstract][Full Text] [Related]
12. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
Tzeng HT; Huang YJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
[TBL] [Abstract][Full Text] [Related]
13. Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy.
He B; Johansson-Percival A; Backhouse J; Li J; Lee GYF; Hamzah J; Ganss R
Cell Rep; 2020 Jan; 30(3):714-724.e5. PubMed ID: 31968248
[TBL] [Abstract][Full Text] [Related]
14. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
15. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy.
Tu J; Liang H; Li C; Huang Y; Wang Z; Chen X; Yuan X
Front Immunol; 2023; 14():1198972. PubMed ID: 37334350
[TBL] [Abstract][Full Text] [Related]
16. Relieving immunosuppression by Endo@PLT targeting anti-angiogenesis to improve the efficacy of immunotherapies.
Chen C; Tang Y; Huang H; Jia L; Feng L; Zhao J; Zhang H; He J; Ding L; Xia D
Chem Commun (Camb); 2022 Mar; 58(19):3202-3205. PubMed ID: 35174839
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
[TBL] [Abstract][Full Text] [Related]
18. Alleviating hypoxia to improve cancer immunotherapy.
Fan P; Zhang N; Candi E; Agostini M; Piacentini M; ; Shi Y; Huang Y; Melino G
Oncogene; 2023 Dec; 42(49):3591-3604. PubMed ID: 37884747
[TBL] [Abstract][Full Text] [Related]
19. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
Front Immunol; 2020; 11():613114. PubMed ID: 33552076
[TBL] [Abstract][Full Text] [Related]
20. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Missiaen R; Mazzone M; Bergers G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]